Delcath Systems to Participate in the Canaccord Virtual MedTech, Diagnostics and Digital Health & Services Forum on November 18, 2021

Rhea-AI Summary

Delcath Systems, a company specializing in interventional oncology, announced its participation in the Canaccord Virtual MedTech, Diagnostics, and Digital Health & Services Forum on November 18, 2021. The event will consist of one-on-one meetings only. Delcath focuses on treating rare liver cancers using its proprietary percutaneous hepatic perfusion (PHP) system, marketed in the U.S. as HEPZATO KIT and in Europe as CHEMOSAT. This innovative system administers high-dose chemotherapy directly to the liver while minimizing systemic side effects.

NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will participate in an upcoming virtual investor conference:

• Canaccord Virtual MedTech, Diagnostics and Digital Health & Services Forum
  • Thursday, November 18, 2021: 1x1 meetings only

To learn more or to schedule a one-on-one meeting with management, please contact your conference representative or james@haydenir.com.

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company’s proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In the United States, the PHP system is being developed under the tradename HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZATO, and is considered a combination drug and device product regulated by the United States Food and Drug Administration (FDA).

In Europe, the PHP system is regulated as a Class IIb medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver.

Contact:

Delcath Investor Relations

Email: investorrelations@delcath.com 

Hayden IR

James Carbonara
(646)-755-7412
james@haydenir.com 

FAQ

When is Delcath Systems participating in the investor conference?

Delcath Systems will participate in the investor conference on November 18, 2021.

What company is hosting the virtual investor conference that Delcath Systems is attending?

The virtual investor conference is hosted by Canaccord.

What is the purpose of Delcath Systems' participation in the conference?

Delcath Systems aims to engage in one-on-one meetings with investors.

What treatment does Delcath Systems focus on?

Delcath Systems focuses on treating primary and metastatic liver cancers.

What is the trade name for Delcath's PHP system in the U.S.?

In the U.S., Delcath's PHP system is marketed as HEPZATO KIT.

What is the regulatory status of Delcath's PHP system in Europe?

In Europe, Delcath's PHP system is regulated as a Class IIb medical device and sold as CHEMOSAT.